Navigation Links
Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
Date:7/10/2008

-- Company Invests in New Production Plant -- Company Expects to Meet Its FY2008 Net Income Make Good Of $5.6 Million,

or EPS of $.18

CHENGDU, China, July 10, 2008 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has completed production for the earthquake relief on May 28 and resumed its normal production.

On May 12, 2008, an 8.0-magnitude earthquake struck in Wenchuan County, Sichuan province. By order of the Sichuan Government, Tianyin is one of the thirty-five pharmaceutical companies within Sichuan province designated to supply medicines for the relief. The Company dedicated its production of medicines for the relief from May 14 to May 28 and resumed its normal production on May 29. The provincial government purchased approximately $725,000 of medicines at full retail price from the Company which included Benorilate Granules (Arpu Shuangxin Oral Liquid), Azithromycin Dispersible Tablets, Yinqiao Shangfeng Capsules, Chuanxinlian Capsules, Qingre Jiedu Capsules and Yinhuang Capsules. Tianyin delivered all the ordered medicines on May 29 and has already received 50% of the payment from the Sichuan Government.

Recently, the management of Tianyin Pharmaceutical started its new production plant project which will enhance its overall production capacity by 3 times with an estimated expenditure of $5 million. The capital need for the expansion was utilized from the recent $15.2 million financing completed in January 2008. The planned GFA is about ten thousand square meters with state- of-the-art equipment which will be installed. Construction will begin in July 2008 and operations are planned to begin in January 2009. The new capacity is expected to meet increasing market demand of current products and support new product lau
'/>"/>

SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
2. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
5. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
6. Texas Detailed Products Today Announced the Second Generation Detail Bag: Skinceuticals Chooses the Detail Bag II Sample Case for all its Pharmaceutical Representatives
7. BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd
8. New Report Examines Pharmaceutical Sales Force Effectiveness
9. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
10. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
11. SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Bavarian Nordic A S Half Year Interim Report 2009 13729 1Bavarian Nordic A S Half Year Interim Report 2009 13729 2Bavarian Nordic A S Half Year Interim Report 2009 13729 3Bavarian Nordic A S Half Year Interim Report 2009 13729 4Bavarian Nordic A S Half Year Interim Report 2009 13729 5Bavarian Nordic A S Half Year Interim Report 2009 13729 6Bavarian Nordic A S Half Year Interim Report 2009 13729 7Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 55591 1Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 55591 2ALOKA Announces New ProSound Alpha Series Ultrasound System 55587 1ALOKA Announces New ProSound Alpha Series Ultrasound System 55587 2ALOKA Announces New ProSound Alpha Series Ultrasound System 55587 3